분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-01-08 01:40:07 , Hit : 1665
 US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments

http://www.in-pharmatechnologist.com/Hot-Topics/Lifecycle-management/Gilead-strikes-back-at-AbbVie-with-exclusive-payer-deal-for-hep-C-drug

By Dan Stanton+

06-Jan-2015
Last updated on 06-Jan-2015 at 15:29 GMT


AbbVie and Gilead have both signed exclusive deals with Pharmacy Benefit Managers for their HCV treatments
AbbVie and Gilead have both signed exclusive deals with Pharmacy Benefit Managers for their HCV treatments


Related tags: Inhibitor, Viekira Pak, Harvoni, Sovaldi, HCV, Olysio, Hepatitis C, AbbVie, Gilead, J&J, Janssen, Express Scripts, CVS

Related topics: Lifecycle management, Drug Delivery, APIs (active pharmaceutical ingredients), Delivery formulations



Gilead and AbbVie’s exclusive deals with payers CVS and Express Scripts could help cut the cost of the new class of treatments for America’s three million Hepatitis C sufferers.



Related news:

Hep C biocatalyst sales slump as Codexis feels Sovaldi impact

Indian drugmakers to bring cheap HCV drug Sovaldi to developing world

Abbvie: Sligo expansion about more than just Hep C candidate

US FDA approves Gilead's $1,125 a pill combination Hep C drug

Generic Sovaldi makers could pocket upwards of $600m says analyst




A number of new drugs for the estimated 3.2 million people in the US living with chronic Hepatitis C virus infection have been launched over the past year, with Abbvie’s drug, Viekira Pak, the latest following its approval by the US Food and Drug Administration (FDA) last month.

The drug combines three active pharmaceutical ingredients (API): an NS5A inhibitor, ombitasvir; NS3/4A protease inhibitor, paritaprevir; and non-nucleoside NS5B polymerase inhibitor, ritonavir.

The triple-action mechanism goes further than Gilead’s two HCV treatments launched in the last year:

Sovaldi (sofosbuvir), a nucleotide analog that inhibits the polymerase enzyme that the hepatitis C virus uses to replicate its RNA, and Harvoni, a combination of sofosbuvir and the drug ledipasvir, which inhibits the viral phosphoprotein, NS5A, involved in viral replication, assembly, and secretion.

These drugs, along with J&J’s Olysio approved in November 2013, can be taken without the need for co-administration of interferon and offer sufferers heightened cure rates with fewer side effects than conventional treatments. Furthermore, the oral delivery method improves patient adherence and compliance.

The impact of these new treatments has already affected sales of other hepatitis C drugs, such as Merck & Co.’s Victrelis - approved for use in combination with peginterferon alfa and ribavirin – which had Q3 2014 sales of $27m , 78% less than the same period 2013.



Similarly, Codexis, which supplies intermediates and biocatalysts for hepatitis C drugs including Victrelis, blamed a 60% drop in sales last August on the impact of Sovaldi.

Price Battle?

However, the benefits of these new drugs come at a cost and Gilead has been hit with criticism regarding its pricing, $84,000 for a 12-week course of Sovaldi , equating to $1,000 a pill, with Harvoni costing even more .

While Viekira Pak has been similarly priced ($83,319), within days of approval AbbVie signed a deal with Express Scripts, the largest Pharmacy Benefit Manager (PBM) in the US, to supply the drug exclusively to HCV sufferers enrolled through its healthcare plan.

ISI analyst Mark Schoenebaum said such a deal coupled with a number of “basically interchangeable” drugs in an “intensively competitive” sector could start a price war between AbbVie and Gilead.

Despite this, he told in-Pharmatechnologist.com the discount AbbVie had offered to gain access with Express Scripts was most likely less than 30% and would only have a “modest” impact on Gilead’s US business.

But yesterday, in what fellow ISI analyst Ross Muken described as “unsurprising but timely,” Gilead announced it too had struck an exclusive deal with the PBM CVS for Harvoni/Sovaldi to be given preferred formulary status.

Describing Gilead’s offerings as more attractive due to the potentially shorter regimen, more convenient dosing, and less drug-to-drug interaction issues, Muken added CVS was likely able to “garner an attractive discount for its members.”

In the UK, the cost of a 12-week course of Sovaldi is £34,983 ($53,155) while in 91 developing countries, a course of the drug will be available for a cost as low as $300 thanks to a tech transfer deal Gilead recently signed with seven Indian generic drugmakers.


Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions







927   바이러스를 저지시키는 방법  이성욱 2014/08/15 1651
926   금발은 어떻게 생겨날까? - DNA 글자 하나가 머리칼의 색깔을 바꾼다.  이성욱 2014/06/05 1652
925   뇌종양이 남성에서 더 흔한 이유?  이성욱 2014/08/06 1655
924   DNA가 비슷한 배우자를 선택하는 경향  이성욱 2014/05/23 1656
923   Pfizer Abandons AstraZeneca Takeover Bid  이성욱 2014/05/29 1657
922   STAP 논문, 결국 62일 만에...  이성욱 2014/04/02 1660
921   유전자요법을 이용한 신경근육접합부 결함 치료  이성욱 2014/09/24 1665
  US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments  이성욱 2015/01/08 1665
919   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1666
918   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1667
917   존재하지 않았던 STAP 줄기세포  이성욱 2014/06/05 1668
916   miRNA를 이용한 계통발생 분석의 문제점  이성욱 2014/08/01 1669
915   텔로머레이즈 기반 유전자 요법으로 심장마비 치료  이성욱 2014/12/24 1670
914   야심찬 브레인 프로젝트  이성욱 2014/06/11 1681
913   박테리아와 바이러스에 존재하는 나노 바이오모터(biomotor)  이성욱 2014/07/18 1682
912   치료가 어려운 C형 간염에 대한 새로운 경구 병용 요법  이성욱 2014/08/01 1683
911   Merck hepatitis C drugs work in HIV co-infected patients -study  이성욱 2014/03/08 1688
910   간에 암 전이가 어떻게 발생하는가  이성욱 2014/10/17 1688
909   Targeting DNA  이성욱 2012/06/07 1698
908   전령 RNA에서의 슈도유리딜화  이성욱 2014/09/19 1698

[이전 10개] [1]..[11][12][13][14][15][16][17] 18 [19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN